JP2020537653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537653A5 JP2020537653A5 JP2020521451A JP2020521451A JP2020537653A5 JP 2020537653 A5 JP2020537653 A5 JP 2020537653A5 JP 2020521451 A JP2020521451 A JP 2020521451A JP 2020521451 A JP2020521451 A JP 2020521451A JP 2020537653 A5 JP2020537653 A5 JP 2020537653A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- composition
- item
- modified
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064086A JP2024086876A (ja) | 2017-10-17 | 2024-04-11 | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573206P | 2017-10-17 | 2017-10-17 | |
| US62/573,206 | 2017-10-17 | ||
| US201762608606P | 2017-12-21 | 2017-12-21 | |
| US62/608,606 | 2017-12-21 | ||
| US201862635277P | 2018-02-26 | 2018-02-26 | |
| US62/635,277 | 2018-02-26 | ||
| PCT/US2018/056077 WO2019079294A1 (en) | 2017-10-17 | 2018-10-16 | RNAI-BASED AGENTS AND COMPOSITIONS FOR INHIBITING ASIALOGLYCOPROTEIN RECEPTOR 1 RECEPTOR 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064086A Division JP2024086876A (ja) | 2017-10-17 | 2024-04-11 | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537653A JP2020537653A (ja) | 2020-12-24 |
| JP2020537653A5 true JP2020537653A5 (enExample) | 2021-11-25 |
| JP7473472B2 JP7473472B2 (ja) | 2024-04-23 |
Family
ID=66173364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521451A Active JP7473472B2 (ja) | 2017-10-17 | 2018-10-16 | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2024064086A Pending JP2024086876A (ja) | 2017-10-17 | 2024-04-11 | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064086A Pending JP2024086876A (ja) | 2017-10-17 | 2024-04-11 | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11492624B2 (enExample) |
| EP (1) | EP3697909A4 (enExample) |
| JP (2) | JP7473472B2 (enExample) |
| CN (1) | CN111212909A (enExample) |
| AU (1) | AU2018352379A1 (enExample) |
| CA (1) | CA3079413A1 (enExample) |
| TW (1) | TW201918555A (enExample) |
| UY (1) | UY37936A (enExample) |
| WO (1) | WO2019079294A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| CN116472063A (zh) * | 2020-11-06 | 2023-07-21 | 阿布特斯生物制药公司 | 包含经修饰的siRNA的靶向性偶联物 |
| CN116617390A (zh) * | 2022-02-11 | 2023-08-22 | 武汉大学 | Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用 |
| WO2024046297A1 (zh) * | 2022-09-02 | 2024-03-07 | 北京福元医药股份有限公司 | 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| CN1300312C (zh) * | 2004-08-23 | 2007-02-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途 |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| US20110150897A1 (en) * | 2006-10-11 | 2011-06-23 | Meyer Thomas F | Influenza targets |
| EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
-
2018
- 2018-10-16 CN CN201880066319.0A patent/CN111212909A/zh active Pending
- 2018-10-16 CA CA3079413A patent/CA3079413A1/en active Pending
- 2018-10-16 WO PCT/US2018/056077 patent/WO2019079294A1/en not_active Ceased
- 2018-10-16 AU AU2018352379A patent/AU2018352379A1/en not_active Abandoned
- 2018-10-16 EP EP18868368.4A patent/EP3697909A4/en active Pending
- 2018-10-16 US US16/756,440 patent/US11492624B2/en active Active
- 2018-10-16 JP JP2020521451A patent/JP7473472B2/ja active Active
- 2018-10-17 UY UY0001037936A patent/UY37936A/es not_active Application Discontinuation
- 2018-10-17 TW TW107136576A patent/TW201918555A/zh unknown
-
2024
- 2024-04-11 JP JP2024064086A patent/JP2024086876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533334A5 (enExample) | ||
| JP2020534268A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| Rigo et al. | Pharmacology of a central nervous system delivered 2′-O-methoxyethyl–modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates | |
| JP2026004402A (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| Iannitti et al. | Phosphorothioate oligonucleotides: effectiveness and toxicity | |
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
| Scoles et al. | Antisense therapies for movement disorders | |
| JP2023519246A5 (enExample) | ||
| CN104994884B (zh) | 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节 | |
| JP2012050438A5 (enExample) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2008510019A5 (enExample) | ||
| JP2018507711A5 (enExample) | ||
| EP4119569A1 (en) | Conjugated antisense compounds for use in therapy | |
| JP2019524151A5 (enExample) | ||
| CA3163490A1 (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv | |
| JP2011515357A5 (enExample) | ||
| JP2011505798A5 (enExample) | ||
| Raghavan et al. | Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammation | |
| JP2020521491A5 (enExample) | ||
| JP2011519365A5 (enExample) | ||
| Lippi et al. | Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI | |
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |